Pooled CRISPR screening identifies m6A as a positive regulator of macrophage activation
Tong J, Wang X, Liu Y, Ren X, Wang A, Chen Z, Yao J, Mao K, Liu T, Meng FL, Pan W, Zou Q, Liu J, Zhou Y, Xia Q, Flavell RA, Zhu S, Li HB. Pooled CRISPR screening identifies m6A as a positive regulator of macrophage activation. Science Advances 2021, 7: eabd4742. PMID: 33910903, PMCID: PMC8081357, DOI: 10.1126/sciadv.abd4742.Peer-Reviewed Original ResearchConceptsMacrophage activationPotential cancer immunotherapy targetInnate immune cellsFaster tumor growthTNF-α productionInnate immune responseCancer immunotherapy targetCre miceImmune cellsImmunotherapy targetImmune responseLPS stimulationTumor growthBacterial infectionsTop candidate genesDeficient macrophagesMultiple cellular responsesMETTL3 deficiencyActivationUnknown roleMETTL3Negative regulatorBinding proteinCellular responsesRNA binding proteinCross-talk of four types of RNA modification writers defines tumor microenvironment and pharmacogenomic landscape in colorectal cancer
Chen H, Yao J, Bao R, Dong Y, Zhang T, Du Y, Wang G, Ni D, Xun Z, Niu X, Ye Y, Li HB. Cross-talk of four types of RNA modification writers defines tumor microenvironment and pharmacogenomic landscape in colorectal cancer. Molecular Cancer 2021, 20: 29. PMID: 33557837, PMCID: PMC7869236, DOI: 10.1186/s12943-021-01322-w.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorColorectal NeoplasmsCombined Modality TherapyComputational BiologyDisease ManagementDisease SusceptibilityEpithelial-Mesenchymal TransitionGene Expression ProfilingGene Expression Regulation, NeoplasticHumansLymphocytes, Tumor-InfiltratingPharmacogeneticsPrognosisProportional Hazards ModelsRNA Processing, Post-TranscriptionalTranscription, GeneticTranscriptomeTumor MicroenvironmentConceptsColorectal cancerConsensus molecular subtypesTumor microenvironmentRNA modification patternsTME cell-infiltrating characteristicsWorse patient overall survivalDevelopment of CRCInhibitory immune cellsPD-L1 blockadeEfficacy of immunotherapyCharacteristics of TMEPatients' overall survivalPotential clinical utilityTherapeutic liabilityOverall survivalClinical featuresClinical benefitPatient survivalImmune cellsM2 macrophagesCRC samplesImmune responseMolecular subtypesClinical utilitySurvival advantage